Day 1 – 21 September 2021
| 09:00–09:25 | Welcome Word |
| 09:25–09:30 | Break |
| Interactive Poster session 1 | |
| 10:15–10:30 | Coffee Break |
| 10:30–11:30 | Industry Symposium 2 |
| 11:30–11:35 | Break |
| 11:35–12:20 | Plenary Session 1 Genetic and epigenetic insights in IgAN Krzysztof Kiryluk: Where are we going next with genetic studies in IgAN? Jonathan Barratt: RNA interference in IgAN Alexandra Cambier: Is there a link between collagen IV mutations and IgAN? |
| 12:20–12:50 | Lunch Break |
| 12:50–13:50 | Free Communications 1 |
| 13:50–13:55 | Break |
| 13:55–14:55 | Panel Discussion 1 Patient panel: The challenges of living with IgA nephropathy |
| 14:55–15:00 | Break |
| 15:00–15:30 | Industry Symposium 6a |
| 15:30–15:35 | Break |
| 15:35–16:20 | Plenary Session 2 What role does complement activation play in IgAN? Richard Lafayette: Complement in IgAN what we know and what we don't Hong Zhang: A role for the lectin pathway? Nick Medjeral-Thomas: A role for the alternative pathway? |
| 16:20–16:35 | Coffee Break |
| 16:35–17:20 | Plenary Session 3 Where do we go next with the kidney biopsy in IgAN? Ian Roberts: What next for the Oxford Classification? Peter Boor: The use of Artificial Intelligence in kidney biopsy evaluation Rafael Kramann: Taking the Omics Revolution into the kidney biopsy |
| 17:20–17:25 | Break |
| 17:25–18:10 | Plenary Session 4 B cells & IgA Jennifer Gommerman: Mucosal immune cells: Saints or Sinners? Jan Novak: 25 years since IgA1 glycosylation changes were first described-what will the next 25 years bring? Loreto Gesualdo: Is IgAN a disease of mistrafficking B cells? |
| 18:10–18:15 | Break |
| 18:15–19:15 | Industry Symposium 2 |
| 19:15–19:20 | Break |
| 19:20–20:20 | Industry Symposium 1 |
| 20:20–20:25 | Break |
| 20:25–21:10 | Interactive Poster session 2 |
|
All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2). |
|
